SurModics (SRDX) Tops Q4 EPS by 11c; Approves Additional $20M Stock Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
SurModics Reports Fourth Quarter Fiscal 2015 Results
November 10, 2015 7:35 AM ESTGAAP Revenue Growth of 13% to $17.4 Million and GAAP EPS of $0.22 Non-GAAP Revenue Up 8% and Non-GAAP EPS of $0.30 FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon Increase in Share Repurchase Authorization to $30.0 Million Fiscal 2016 Guidance Outlined
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2015 fourth... More
